A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon Compared to GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Dasiglucagon (Primary) ; Glucagon
- Indications Hypoglycaemia
- Focus Adverse reactions; Registrational
- Sponsors Zealand Pharma
- 07 Dec 2017 According to a Zealand Pharma media release, results are expected in Q2 2018, ahead of previous expectations.
- 08 Nov 2017 According to a Zealand Pharma media release, status changed from recruiting to active, no longer recruiting.
- 10 Jul 2017 Planned End Date changed from 19 Dec 2017 to 27 Feb 2018.